Candel Therapeutics (CADL) Free Cash Flow: 2020-2023
Historic Free Cash Flow for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to -$7.5 million.
- Candel Therapeutics' Free Cash Flow fell 4.30% to -$7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$34.7 million, marking a year-over-year decrease of 6.07%. This contributed to the annual value of -$27.0 million for FY2024, which is 22.08% up from last year.
- Per Candel Therapeutics' latest filing, its Free Cash Flow stood at -$7.5 million for Q4 2023, which was up 16.18% from -$8.9 million recorded in Q3 2023.
- Over the past 5 years, Candel Therapeutics' Free Cash Flow peaked at -$2.2 million during Q3 2020, and registered a low of -$11.0 million during Q1 2023.
- Its 3-year average for Free Cash Flow is -$7.6 million, with a median of -$7.5 million in 2021.
- Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 196.41% in 2021, then grew by 7.17% in 2023.
- Over the past 4 years, Candel Therapeutics' Free Cash Flow (Quarterly) stood at -$3.9 million in 2020, then crashed by 48.41% to -$5.7 million in 2021, then decreased by 24.71% to -$7.2 million in 2022, then declined by 4.30% to -$7.5 million in 2023.
- Its last three reported values are -$7.5 million in Q4 2023, -$8.9 million for Q3 2023, and -$7.4 million during Q2 2023.